SEARCH

SEARCH BY CITATION

References

  • 1
    Gunnarsson R, Löfmark R, Nordlander R, Nyquist O, Groth C.-G. Acute myocardial infarction in renal transplant recipients: incidence and prognosis. Eur Heart J 1984; 5: 218221.
  • 2
    Uretsky BF, Murali S, Reddy PS, Rabbin B, Lee A, Griffith BP, Hardesty RL. et al. Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation 1987; 76: 827833.
  • 3
    Drüeke TB, Abdulmassih Z, Lacour B, Bader C, Chevalier A, Kreis H. Atherosclerosis and lipid disorders after renal transplantation. Kidney Int 1991; 39(suppl 31): 2428.
  • 4
    López-Mir an da J, Pérez-Jiménez F, Torres A, Espino-Montoro A, Gomez P, Hidalgo-Rojas L, Ordovas MJ. et al. Effects of cyclosporine on plasma lipoproteins in bone marrow transplantation patients. Clin Biochem 1992; 25: 379386.
  • 5
    Stone JN. Secondary causes of hyperlipidaemia. Med Clin North Am 1994; 78: 117141.
  • 6
    Awni WM, Heim-Duthoy K, Kasiske BL. Impact of lipoproteins on cyclosporine pharamacokinetics and biological activity in transplant patients. Transplant Proc 1990; 22: 11931196.
  • 7
    Gardier AM, Mathé D, Huédeney X, Barré J, Benvenutti C, Navarro N, Vernillet L. et al. Effects of plasma lipids level on blood distribution and pharmacokinetics of Cyclosporin A. Ther Drug Monit 1993; 15: 274280.
  • 8
    Havel RJ, Goldstein JL, Brown MS. Lipoproteins and lipid transports. In: BondyPK and RosenbergLE. eds. Metabolic control and disease. Philadelphia, PA: Saunders, 1980: 393494.
  • 9
    Havel RJ, Hamilton RL. Hepatocytic lipoprotein receptors and intracellular lipoprotein catabolism. Hepatology 1988; 8: 16891704.
  • 10
    Kaptein A, de Wit ECM, Princen HMG. Cotranslational inhibition of apoB-100 synthesis by Cyclosporin A in the human hepatoma cell line HepG2. Arterioscler Thromb 1994; 14: 780789.
  • 11
    Javitt NB. HepG2 cells as a resource for metabolic studies: lipoproteins, cholesterol, and bile acids. FASEB J 1990; 4: 161168.
  • 12
    Havekes L, Van Hinsbergh V, Kempen HL, Eneis J. The metabolism in vitro of human low-density lipoprotein by human hepatoma cell line HepG2. Biochem J 1983; 214: 951958.
  • 13
    Havel RJ, Eder HA, Bragdon JH. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J Clin Invest 1955; 34: 13451353.
  • 14
    McFarlane AS. Efficient trace-labelling of proteins with iodine. Nature 1958; 182: 53.
  • 15
    Bierman RL, Stein O, Stein Y. Lipoprotein uptake and metabolism by aortic smooth muscle cells in tissue culture. Circ Res 1974; 35: 136150.
  • 16
    Beisiegel U, Schneider WJ, Goldstein JL, Andersson RGW, Brown MS. Monoclonal antibodies to the low-density lipoprotein receptors as probes for study of receptor-mediated endocytosis and the genetics of familial hypercholesterolemia. J Biol Chem 1981; 256: 1192311931.
  • 17
    Salter AM, Saxton J, Brindley D. Characterization of the binding of human low-density lipoprotein to primary monolayer cultures of rat hepatocytes. Biochem J 1986; 240: 549557.
  • 18
    Rödl S, Khoshsorus G. Binding of Cyclosporine A to human serum lipoproteins. Transplant Proc 1990; 22: 287288.
  • 19
    Ausubel MA, Bernt R, Kingston RE, Moore DD, Seidman JG, Smith JA. and Struhl K Preparation and analysis of RNA.In: Current protocols in molecular biology. Green Publishing Associates, Inc. and Wiley; 1993: 1.
  • 20
    Yamamoto T, Davis CG, Brown MS, Schneider WJ, Casey ML, Goldstein JL, Russel DW. The human LDL receptor: a cysteine-rich protein with multiple Alu sequences in its mRNA. Cell 1984; 39: 2738.
  • 21
    Lelli N, Ghisellinin M, Gualdi R, Tiozzo R, Calandra S, Gaddi A, Ciarrocchi A. et al. Characterization of three mutations of low-density lipoprotein receptor gene in Italian patients with familial hypercholesterolemia. Arterioscler Thromb 1991; 11: 234243.
  • 22
    Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurements with folin phenol reagents. J Biol Chem 1951; 193: 265275.
  • 23
    Liao W, Florén CH. Endotoxins inhibit endocytic catabolism of low-density lipoproteins in HepG2 cells. Hepatology 1992; 16: 224231.
  • 24
    Ellsworth JL, Erickson SK, Cooper AD. Very low- and low-density lipoprotein synthesis and secretion by the human hepatoma cell line HepG2 cells: effect of free fatty acid. J Lipid Res 1986; 27: 858874.
  • 25
    Wang SR, Pessah M, Infante J, Catala D, Salvat C, Infante R. Lipid and lipoprotein metabolism in HepG2 cells. Biochim Biophys Acta 1988; 961: 351363.